Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:KYMR NYSE:QGEN NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.67$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsKYMRKymera Therapeutics$84.10-2.3%$84.25$28.06▼$103.00$6.92B2.06691,662 shs467,535 shsQGENQiagen$32.63-1.3%$40.93$32.60▼$57.81$6.72B0.642.31 million shs1.82 million shsVCELVericel$32.92-1.6%$33.93$28.95▼$45.97$1.68B1.15603,464 shs827,670 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.21%+66.89%+99.19%KYMRKymera Therapeutics0.00%+6.65%+1.21%+8.93%+186.27%QGENQiagen0.00%-3.47%-19.19%-34.88%-25.02%VCELVericel0.00%-5.93%-0.71%-5.59%-19.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.67$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsKYMRKymera Therapeutics$84.10-2.3%$84.25$28.06▼$103.00$6.92B2.06691,662 shs467,535 shsQGENQiagen$32.63-1.3%$40.93$32.60▼$57.81$6.72B0.642.31 million shs1.82 million shsVCELVericel$32.92-1.6%$33.93$28.95▼$45.97$1.68B1.15603,464 shs827,670 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.21%+66.89%+99.19%KYMRKymera Therapeutics0.00%+6.65%+1.21%+8.93%+186.27%QGENQiagen0.00%-3.47%-19.19%-34.88%-25.02%VCELVericel0.00%-5.93%-0.71%-5.59%-19.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.11Hold$111.87-2.78% DownsideKYMRKymera Therapeutics 2.96Moderate Buy$118.1040.42% UpsideQGENQiagen 2.50Moderate Buy$46.3842.15% UpsideVCELVericel 2.63Moderate Buy$55.4068.29% UpsideCurrent Analyst Ratings BreakdownLatest VCEL, QGEN, ACLX, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026VCELVericel HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$64.005/7/2026QGENQiagen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$46.00 ➝ $40.005/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/30/2026QGENQiagen Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.004/29/2026QGENQiagen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$44.00 ➝ $38.004/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Outperform$53.00 ➝ $43.004/29/2026ACLXArcellx Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral4/29/2026QGENQiagen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy$43.004/29/2026QGENQiagen JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$60.00 ➝ $45.00(Data available from 5/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$22.29M301.95N/AN/A$6.96 per share16.53KYMRKymera Therapeutics$51.48M134.39N/AN/A$19.42 per share4.33QGENQiagen$2.10B3.20$3.36 per share9.70$17.89 per share1.82VCELVericel$276.26M6.09$0.55 per share60.23$7.01 per share4.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$228.93M-$4.07N/AN/AN/A-1,027.26%-55.42%-36.24%N/AKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/AQGENQiagen$424.88M$1.9117.0412.133.2919.16%14.09%8.26%N/AVCELVericel$16.52M$0.4278.3842.75N/A7.35%6.41%4.61%7/30/2026 (Estimated)Latest VCEL, QGEN, ACLX, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/7/2026Q1 2026VCELVericel-$0.15-$0.12+$0.03-$0.12$63.68 million$68.43 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million2/26/2026Q4 2025ACLXArcellx-$1.01-$1.01N/A-$1.01$13.40 million$1.65 million2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 million2/26/2026Q4 2025VCELVericel$0.45$0.45N/A$0.45$92.66 million$92.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AQGENQiagen$0.260.80%N/A13.61%N/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.444.44KYMRKymera TherapeuticsN/A10.8110.81QGENQiagen0.443.903.31VCELVericelN/A5.184.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%KYMRKymera TherapeuticsN/AQGENQiagen70.00%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx8.35%KYMRKymera Therapeutics16.01%QGENQiagen9.00%VCELVericel7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8058.48 million53.60 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableQGENQiagen5,654206.08 million187.53 millionOptionableVCELVericel30051.07 million47.19 millionOptionableVCEL, QGEN, ACLX, and KYMR HeadlinesRecent News About These CompaniesHC Wainwright Has Positive Estimate for Vericel Q4 EarningsMay 11 at 1:38 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for Vericel Q4 Earnings?May 11 at 1:37 AM | marketbeat.comVericel (NASDAQ:VCEL) Shares Down 9.1% - Time to Sell?May 10 at 4:43 AM | americanbankingnews.comVericel Corporation 2026 Q1 - Results - Earnings Call PresentationMay 9 at 7:41 PM | seekingalpha.comAnalysts Have Made A Financial Statement On Vericel Corporation's (NASDAQ:VCEL) First-Quarter ReportMay 9 at 5:57 PM | finance.yahoo.comVericel (VCEL) Q1 2026 Earnings TranscriptMay 9 at 7:55 AM | finance.yahoo.comVericel Q1 Earnings Call HighlightsMay 9 at 2:06 AM | marketbeat.comVericel Earnings Call Signals Accelerating Growth and MarginsMay 8 at 9:50 PM | tipranks.comVericel (NASDAQ:VCEL) Trading Down 9.1% - What's Next?May 8 at 1:22 PM | marketbeat.comVericel Corporation (VCEL) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comVericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPSMay 7, 2026 | marketbeat.comVericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue EstimatesMay 7, 2026 | zacks.comVericel (NASDAQ:VCEL) Shares Gap Up on Strong EarningsMay 7, 2026 | marketbeat.comVericel Corporation Reports 30% Revenue Growth to $68.4 Million in Q1 2026, Raises Full-Year Guidance to $326-$336 MillionMay 7, 2026 | quiverquant.comQVericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial GuidanceMay 7, 2026 | globenewswire.comVericel Q1 2026 earnings previewMay 7, 2026 | msn.comWall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a BetMay 4, 2026 | zacks.comVericel Corporation (NASDAQ:VCEL) Receives $55.40 Average PT from AnalystsMay 3, 2026 | americanbankingnews.comVericel Shareholders Reaffirm Board, Pay Plan, AuditorMay 1, 2026 | tipranks.comConestoga Capital Advisors LLC Acquires 79,278 Shares of Vericel Corporation $VCELMay 1, 2026 | marketbeat.comVericel Annual Meeting: Shareholders Elect Seven Directors, Approve Say-on-Pay and PwC AuditorMay 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCEL, QGEN, ACLX, and KYMR Company DescriptionsArcellx NASDAQ:ACLXArcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Kymera Therapeutics NASDAQ:KYMR$84.10 -1.98 (-2.30%) Closing price 04:00 PM EasternExtended Trading$84.06 -0.03 (-0.04%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Qiagen NYSE:QGEN$32.63 -0.41 (-1.25%) Closing price 03:59 PM EasternExtended Trading$32.64 +0.01 (+0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Vericel NASDAQ:VCEL$32.92 -0.54 (-1.61%) Closing price 04:00 PM EasternExtended Trading$32.90 -0.02 (-0.05%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now Tapestry Stock Drops After Strong Quarter and Raised Outlook MarketBeat Week in Review – 05/04 - 05/08 Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
